#USA #San Diego #Inhibrx #ESMO Congress #Ewing Sarcoma

Inhibrx Biosciences to Present at ESMO Sarcoma Congress

Inhibrx Biosciences, Inc., a prominent clinical-stage biopharmaceutical company, has officially announced its participation in the upcoming ESMO Sarcoma and Rare Cancers Congress, which is scheduled to take place from March 12th to 14th, 2026, in Lugano, Switzerland. This prestigious event is a significant platform for sharing innovative research in the field of oncology, particularly focusing on rare cancer types, including Ewing Sarcoma.

Key Presentation Details

The highlight of Inhibrx's participation will be the presentation on a key study title: "Phase 1 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan and Temozolomide in Adolescents and Adults with Ewing Sarcoma". This fascinating study will delve into the efficacy of the novel compound Ozekibart, which is designed to target and activate specific cancer signaling pathways, showcasing its potential in treating Ewing Sarcoma.

Presentation Schedule

The presenting author, Dr. Ana Sebio, M.D., Ph.D., along with lead author Dr. Rashmi Chugh, M.D., will introduce their findings during Mini Oral Session 1 on Thursday, March 12th, 2026, at 11:30 AM CET. The session will be held in Hall A at Palazzo dei Congressi in Lugano. Attendees can expect a comprehensive overview of the data supporting Ozekibart's therapeutic potential, as well as discussions surrounding its application with established chemotherapeutics Irinotecan and Temozolomide, commonly used for treating various cancers including Ewing Sarcoma.

About The Drug Ozekibart

Ozekibart is a tetravalent agonist targeting DR5, a receptor implicated in apoptosis (programmed cell death) pathways in cancer cells. By harnessing advanced protein engineering techniques, Inhibrx aims to optimize the drug's valency, potentially offering a targeted approach to enhance patient outcomes in hard-to-treat cancers. This innovative methodology reflects Inhibrx’s commitment to advancing therapeutic options in oncology, specifically for patients fighting rare cancers.

Inhibrx's Commitments and Future Outlook

Founded as a wholly-owned subsidiary of Inhibrx, Inc. in January 2024, Inhibrx Biosciences is dedicated to introducing a broad pipeline of biologic therapeutic candidates. The company employs cutting-edge protein engineering to meet the challenges posed by the complex biology of cancer. Following their recent restructuring, Inhibrx has expanded its focus, now prioritizing innovative treatment pathways, as evidenced by the development of Ozekibart.

In anticipation of the ESMO Congress, Inhibrx recommends interested investors and media individuals to access real-time updates and presentation details through the investors’ section of the Inhibrx website. The presentation will be streamed via a designated link, ensuring that stakeholders can stay informed on this pivotal discussion in cancer treatment.

As Inhibrx prepares to showcase its latest research, the upcoming ESMO Congress stands as a testament to the critical advancements being made in the field of rare cancers. The company’s focus on developing groundbreaking therapies holds promise for better treatment options and improved quality of life for patients suffering from Ewing Sarcoma and other rare cancers. This participation could ultimately position Inhibrx as a leading contributor in the ongoing battle against cancer.

For further details, visit Inhibrx’s Official Website.